Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Regulatory considerations for nucleic acid vaccines

H A Smith

    Vaccine
    |December 1, 1994
    PubMed
    Summary

    Nucleic acid vaccines, regulated as biological products by the Center for Biologics Evaluation and Research (CBER), face similar regulatory scrutiny as other vaccines. Guidance covers manufacturing, preclinical, and clinical evaluations for these novel therapeutics.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A staged and layered approach to restoring turbid nearshore coral reefs.

    Journal of environmental management·2025
    Same author

    Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

    Physical review letters·2025
    Same author

    Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS Detector.

    Physical review letters·2025
    Same author

    Disentangling Sources of Momentum Fluctuations in Xe+Xe and Pb+Pb Collisions with the ATLAS Detector.

    Physical review letters·2025
    Same author

    Search for Light Long-Lived Particles in pp Collisions at sqrt[s]=13  TeV Using Displaced Vertices in the ATLAS Inner Detector.

    Physical review letters·2024
    Same author

    Search for the Exclusive W Boson Hadronic Decays W^{±}→π^{±}γ, W^{±}→K^{±}γ and W^{±}→ρ^{±}γ with the ATLAS Detector.

    Physical review letters·2024

    Area of Science:

    • Biologics and Vaccines
    • Regulatory Science
    • Molecular Biology

    Background:

    • Nucleic acid vaccines represent a novel class of biological products with potential for broad application in infectious disease prevention and therapeutic treatment.
    • The Center for Biologics Evaluation and Research (CBER) oversees the regulation of biological products, including emerging vaccine technologies.
    • Existing regulatory frameworks for biological products are largely applicable to nucleic acid vaccines, necessitating a clear understanding of CBER's organizational structure and review processes.

    Purpose of the Study:

    • To provide an overview of the Center for Biologics Evaluation and Research (CBER) organization and its review process for nucleic acid vaccines.
    • To describe the relevant US Code of Federal Regulations and CBER guidance documents applicable to nucleic acid vaccine regulation.
    • To highlight specific regulatory considerations for the manufacturing, lot release, and preclinical safety assessment of polynucleotide vaccines.

    Main Methods:

    • Review of existing regulations in the US Code of Federal Regulations governing biological products.
    • Analysis of guidance documents, including Points to Consider documents and specific guidelines, provided by CBER.
    • Description of the Investigational New Drug (IND) application process and clinical study protocol design for nucleic acid vaccines.

    Main Results:

    • Nucleic acid vaccines are classified as biological products and fall under CBER's regulatory purview.
    • Regulatory concerns for nucleic acid vaccines mirror those of other biological products, encompassing manufacturing, preclinical evaluation, and clinical studies.
    • Specific guidance exists for manufacturing, lot release, and preclinical safety assessment, alongside the established IND submission process.

    Conclusions:

    • Nucleic acid vaccines will be regulated by CBER, leveraging existing frameworks for biological products.
    • Adherence to CBER regulations and guidance is crucial for the development and approval of these vaccines.
    • A thorough understanding of the regulatory pathway, from manufacturing to clinical trials, is essential for advancing nucleic acid vaccine technology.

    Related Experiment Videos